Prostate adenocarcinoma grade group 1: Rationale for retaining a cancer label in the 2022 World Health Organization classification

Authors list

George J Netto Mahul B Amin Eva M Compérat Anthony J Gill Arndt Hartmann Holger Moch Santosh Menon Maria R Raspollini Mark A Rubin John R Srigley Puay Hoon Tan Satish K Tickoo Toyonori Tsuzuki Samra Turajlic Ian Cree Daniel M Berney
Scroll for detail on labs, facilities & authors

Abstract

We present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.

Journal details

Journal European Urology
Volume 83
Issue number 4
Pages 301-303
Available online
Publication date

Full text links

Publisher website (DOI) 10.1016/j.eururo.2022.09.015
Europe PubMed Central 36202687
Pubmed 36202687

Keywords

Related topics
Type of publication

Crick labs/facilities

Crick authors

Crick First author
Crick Corresponding author

Related content